Does the media favor NEOG or MMSI?

In the previous week, Neogen had 2 more articles in the media than Merit Medical Systems. MarketBeat recorded 6 mentions for Neogen and 4 mentions for Merit Medical Systems. Merit Medical Systems' average media sentiment score of 1.25 beat Neogen's score of 0.10 indicating that Merit Medical Systems is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neogen 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Merit Medical Systems 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, ICUI or NEOG?

ICU Medical has higher revenue and earnings than Neogen. Neogen is trading at a lower price-to-earnings ratio than ICU Medical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ICU Medical $2.23B 1.53 $730K $1.85 73.84 Neogen $894.66M 2.17 -$1.09B -$2.80 N/A

Is ICUI or NEOG more profitable?

ICU Medical has a net margin of 2.15% compared to Neogen's net margin of -69.93%. ICU Medical's return on equity of 7.50% beat Neogen's return on equity. Company Net Margins Return on Equity Return on Assets ICU Medical 2.15% 7.50% 3.91% Neogen -69.93% 2.35% 1.46%

Does the media favor ICUI or NEOG?

In the previous week, Neogen had 5 more articles in the media than ICU Medical. MarketBeat recorded 6 mentions for Neogen and 1 mentions for ICU Medical. ICU Medical's average media sentiment score of 1.58 beat Neogen's score of 0.10 indicating that ICU Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ICU Medical 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Neogen 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, HAE or NEOG?

Haemonetics has higher revenue and earnings than Neogen. Neogen is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Haemonetics $1.33B 2.43 $97.31M $2.02 35.30 Neogen $894.66M 2.17 -$1.09B -$2.80 N/A

Is HAE or NEOG more profitable?

Haemonetics has a net margin of 7.29% compared to Neogen's net margin of -69.93%. Haemonetics' return on equity of 27.30% beat Neogen's return on equity. Company Net Margins Return on Equity Return on Assets Haemonetics 7.29% 27.30% 9.59% Neogen -69.93% 2.35% 1.46%

Does the media prefer HAE or NEOG?

In the previous week, Haemonetics had 3 more articles in the media than Neogen. MarketBeat recorded 9 mentions for Haemonetics and 6 mentions for Neogen. Neogen's average media sentiment score of 0.10 beat Haemonetics' score of -0.18 indicating that Neogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Haemonetics 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Neogen 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to NEOG or XRAY?

In the previous week, Neogen had 2 more articles in the media than DENTSPLY SIRONA. MarketBeat recorded 6 mentions for Neogen and 4 mentions for DENTSPLY SIRONA. DENTSPLY SIRONA's average media sentiment score of 0.49 beat Neogen's score of 0.10 indicating that DENTSPLY SIRONA is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neogen 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral DENTSPLY SIRONA 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is STAA or NEOG more profitable?

STAAR Surgical has a net margin of -7.24% compared to Neogen's net margin of -69.93%. STAAR Surgical's return on equity of 3.31% beat Neogen's return on equity. Company Net Margins Return on Equity Return on Assets STAAR Surgical -7.24% 3.31% 2.55% Neogen -69.93% 2.35% 1.46%

Does the media favor STAA or NEOG?

In the previous week, Neogen had 4 more articles in the media than STAAR Surgical. MarketBeat recorded 6 mentions for Neogen and 2 mentions for STAAR Surgical. STAAR Surgical's average media sentiment score of 0.22 beat Neogen's score of 0.10 indicating that STAAR Surgical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment STAAR Surgical 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Neogen 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Neogen (NEOG) Competitors

$8.90 -0.22 (-2.41%)

Closing price 06/5/2026 04:00 PM Eastern

Extended Trading

$8.95 +0.05 (+0.56%)

As of 06/5/2026 04:58 PM Eastern

Compare

NEOG vs. MMSI, ICUI, HAE, XRAY, and STAA

Should you buy Neogen stock or one of its competitors? MarketBeat compares Neogen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Neogen include Merit Medical Systems (MMSI), ICU Medical (ICUI), Haemonetics (HAE), DENTSPLY SIRONA (XRAY), and STAAR Surgical (STAA). These companies are all part of the "health care supplies" industry.

How does Neogen compare to Merit Medical Systems?

Neogen (NASDAQ:NEOG) and Merit Medical Systems (NASDAQ:MMSI) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

Neogen currently has a consensus target price of $10.67, suggesting a potential upside of 19.85%. Merit Medical Systems has a consensus target price of $92.80, suggesting a potential upside of 43.92%. Given Merit Medical Systems' stronger consensus rating and higher possible upside, analysts clearly believe Merit Medical Systems is more favorable than Neogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neogen	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
Merit Medical Systems	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

In the previous week, Neogen had 2 more articles in the media than Merit Medical Systems. MarketBeat recorded 6 mentions for Neogen and 4 mentions for Merit Medical Systems. Merit Medical Systems' average media sentiment score of 1.25 beat Neogen's score of 0.10 indicating that Merit Medical Systems is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neogen	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Merit Medical Systems	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Merit Medical Systems has a net margin of 9.03% compared to Neogen's net margin of -69.93%. Merit Medical Systems' return on equity of 13.54% beat Neogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neogen	-69.93%	2.35%	1.46%
Merit Medical Systems	9.03%	13.54%	7.94%

96.7% of Neogen shares are owned by institutional investors. Comparatively, 99.7% of Merit Medical Systems shares are owned by institutional investors. 0.6% of Neogen shares are owned by company insiders. Comparatively, 0.7% of Merit Medical Systems shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Neogen has a beta of 1.8, meaning that its share price is 80% more volatile than the broader market. Comparatively, Merit Medical Systems has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market.

Merit Medical Systems has higher revenue and earnings than Neogen. Neogen is trading at a lower price-to-earnings ratio than Merit Medical Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neogen	$894.66M	2.17	-$1.09B	-$2.80	N/A
Merit Medical Systems	$1.52B	2.54	$128.49M	$2.31	27.91

Summary

Merit Medical Systems beats Neogen on 14 of the 16 factors compared between the two stocks.

How does Neogen compare to ICU Medical?

ICU Medical (NASDAQ:ICUI) and Neogen (NASDAQ:NEOG) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

ICU Medical currently has a consensus price target of $168.00, indicating a potential upside of 22.98%. Neogen has a consensus price target of $10.67, indicating a potential upside of 19.85%. Given ICU Medical's stronger consensus rating and higher probable upside, analysts clearly believe ICU Medical is more favorable than Neogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ICU Medical	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00
Neogen	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

In the previous week, Neogen had 5 more articles in the media than ICU Medical. MarketBeat recorded 6 mentions for Neogen and 1 mentions for ICU Medical. ICU Medical's average media sentiment score of 1.58 beat Neogen's score of 0.10 indicating that ICU Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ICU Medical	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Neogen	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ICU Medical has a net margin of 2.15% compared to Neogen's net margin of -69.93%. ICU Medical's return on equity of 7.50% beat Neogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ICU Medical	2.15%	7.50%	3.91%
Neogen	-69.93%	2.35%	1.46%

ICU Medical has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market. Comparatively, Neogen has a beta of 1.8, indicating that its stock price is 80% more volatile than the broader market.

96.1% of ICU Medical shares are owned by institutional investors. Comparatively, 96.7% of Neogen shares are owned by institutional investors. 2.1% of ICU Medical shares are owned by insiders. Comparatively, 0.6% of Neogen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

ICU Medical has higher revenue and earnings than Neogen. Neogen is trading at a lower price-to-earnings ratio than ICU Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ICU Medical	$2.23B	1.53	$730K	$1.85	73.84
Neogen	$894.66M	2.17	-$1.09B	-$2.80	N/A

Summary

ICU Medical beats Neogen on 13 of the 17 factors compared between the two stocks.

How does Neogen compare to Haemonetics?

Haemonetics (NYSE:HAE) and Neogen (NASDAQ:NEOG) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership.

Haemonetics has higher revenue and earnings than Neogen. Neogen is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Haemonetics	$1.33B	2.43	$97.31M	$2.02	35.30
Neogen	$894.66M	2.17	-$1.09B	-$2.80	N/A

Haemonetics has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, Neogen has a beta of 1.8, suggesting that its share price is 80% more volatile than the broader market.

99.7% of Haemonetics shares are held by institutional investors. Comparatively, 96.7% of Neogen shares are held by institutional investors. 1.8% of Haemonetics shares are held by company insiders. Comparatively, 0.6% of Neogen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Haemonetics presently has a consensus target price of $77.11, indicating a potential upside of 8.14%. Neogen has a consensus target price of $10.67, indicating a potential upside of 19.85%. Given Neogen's higher probable upside, analysts plainly believe Neogen is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Haemonetics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
Neogen	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

In the previous week, Haemonetics had 3 more articles in the media than Neogen. MarketBeat recorded 9 mentions for Haemonetics and 6 mentions for Neogen. Neogen's average media sentiment score of 0.10 beat Haemonetics' score of -0.18 indicating that Neogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Haemonetics	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Neogen	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Haemonetics has a net margin of 7.29% compared to Neogen's net margin of -69.93%. Haemonetics' return on equity of 27.30% beat Neogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Haemonetics	7.29%	27.30%	9.59%
Neogen	-69.93%	2.35%	1.46%

Summary

Haemonetics beats Neogen on 14 of the 17 factors compared between the two stocks.

How does Neogen compare to DENTSPLY SIRONA?

Neogen (NASDAQ:NEOG) and DENTSPLY SIRONA (NASDAQ:XRAY) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation.

In the previous week, Neogen had 2 more articles in the media than DENTSPLY SIRONA. MarketBeat recorded 6 mentions for Neogen and 4 mentions for DENTSPLY SIRONA. DENTSPLY SIRONA's average media sentiment score of 0.49 beat Neogen's score of 0.10 indicating that DENTSPLY SIRONA is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neogen	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
DENTSPLY SIRONA	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

DENTSPLY SIRONA has higher revenue and earnings than Neogen. Neogen is trading at a lower price-to-earnings ratio than DENTSPLY SIRONA, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neogen	$894.66M	2.17	-$1.09B	-$2.80	N/A
DENTSPLY SIRONA	$3.68B	0.54	-$598M	-$3.15	N/A

DENTSPLY SIRONA has a net margin of -17.06% compared to Neogen's net margin of -69.93%. DENTSPLY SIRONA's return on equity of 18.83% beat Neogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neogen	-69.93%	2.35%	1.46%
DENTSPLY SIRONA	-17.06%	18.83%	5.13%

Neogen presently has a consensus price target of $10.67, suggesting a potential upside of 19.85%. DENTSPLY SIRONA has a consensus price target of $13.55, suggesting a potential upside of 35.45%. Given DENTSPLY SIRONA's higher possible upside, analysts plainly believe DENTSPLY SIRONA is more favorable than Neogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neogen	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
DENTSPLY SIRONA	3 Sell rating(s)	8 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.00

Neogen has a beta of 1.8, indicating that its stock price is 80% more volatile than the broader market. Comparatively, DENTSPLY SIRONA has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market.

96.7% of Neogen shares are held by institutional investors. Comparatively, 95.7% of DENTSPLY SIRONA shares are held by institutional investors. 0.6% of Neogen shares are held by company insiders. Comparatively, 0.5% of DENTSPLY SIRONA shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

DENTSPLY SIRONA beats Neogen on 9 of the 16 factors compared between the two stocks.

How does Neogen compare to STAAR Surgical?

STAAR Surgical (NASDAQ:STAA) and Neogen (NASDAQ:NEOG) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

STAAR Surgical has a beta of 1.23, suggesting that its stock price is 23% more volatile than the broader market. Comparatively, Neogen has a beta of 1.8, suggesting that its stock price is 80% more volatile than the broader market.

STAAR Surgical currently has a consensus price target of $27.81, suggesting a potential downside of 7.26%. Neogen has a consensus price target of $10.67, suggesting a potential upside of 19.85%. Given Neogen's stronger consensus rating and higher possible upside, analysts clearly believe Neogen is more favorable than STAAR Surgical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
STAAR Surgical	2 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.09
Neogen	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

96.7% of STAAR Surgical shares are owned by institutional investors. Comparatively, 96.7% of Neogen shares are owned by institutional investors. 39.9% of STAAR Surgical shares are owned by insiders. Comparatively, 0.6% of Neogen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Neogen had 4 more articles in the media than STAAR Surgical. MarketBeat recorded 6 mentions for Neogen and 2 mentions for STAAR Surgical. STAAR Surgical's average media sentiment score of 0.22 beat Neogen's score of 0.10 indicating that STAAR Surgical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
STAAR Surgical	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Neogen	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

STAAR Surgical has higher earnings, but lower revenue than Neogen. STAAR Surgical is trading at a lower price-to-earnings ratio than Neogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
STAAR Surgical	$239.44M	6.24	-$80.45M	-$0.43	N/A
Neogen	$894.66M	2.17	-$1.09B	-$2.80	N/A

STAAR Surgical has a net margin of -7.24% compared to Neogen's net margin of -69.93%. STAAR Surgical's return on equity of 3.31% beat Neogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
STAAR Surgical	-7.24%	3.31%	2.55%
Neogen	-69.93%	2.35%	1.46%

Summary

STAAR Surgical beats Neogen on 9 of the 16 factors compared between the two stocks.

Get Neogen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NEOG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NEOG vs. The Competition

Export

Metric	Neogen	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.94B	$8.48B	$6.68B	$11.99B
Dividend Yield	N/A	2.52%	2.67%	5.55%
P/E Ratio	-3.18	13.01	20.29	21.86
Price / Sales	2.17	6.93	519.33	112.45
Price / Cash	1.54	17.18	42.23	54.60
Price / Book	0.93	3.56	9.73	6.35
Net Income	-$1.09B	$224.05M	$3.57B	$337.59M
7 Day Performance	-0.78%	-2.11%	-1.26%	-2.51%
1 Month Performance	-3.05%	1.53%	0.82%	-0.69%
1 Year Performance	70.83%	-3.59%	24.09%	25.37%

Neogen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NEOG Neogen	1.7958 of 5 stars	$8.90 -2.4%	$10.67 +19.9%	+81.3%	$1.94B	$894.66M	N/A	2,110	News Coverage
MMSI Merit Medical Systems	4.7291 of 5 stars	$62.05 -1.6%	$92.80 +49.6%	-32.3%	$3.76B	$1.54B	26.86	7,500
ICUI ICU Medical	3.828 of 5 stars	$131.64 -2.8%	$168.00 +27.6%	+2.8%	$3.38B	$2.23B	71.16	13,000
HAE Haemonetics	2.2228 of 5 stars	$67.37 -0.6%	$77.11 +14.5%	+1.2%	$3.08B	$1.33B	33.35	3,009	Analyst Revision
XRAY DENTSPLY SIRONA	4.5069 of 5 stars	$10.02 -4.3%	$13.82 +37.9%	-37.1%	$2.10B	$3.68B	N/A	14,000	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NEOG) was last updated on 6/6/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neogen (NEOG) Competitors

NEOG vs. MMSI, ICUI, HAE, XRAY, and STAA

How does Neogen compare to Merit Medical Systems?

Summary

How does Neogen compare to ICU Medical?

Summary

How does Neogen compare to Haemonetics?

Summary

How does Neogen compare to DENTSPLY SIRONA?

Summary

How does Neogen compare to STAAR Surgical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEOG vs. The Competition

Neogen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neogen (NEOG) Competitors

NEOG vs. MMSI, ICUI, HAE, XRAY, and STAA

How does Neogen compare to Merit Medical Systems?

Do analysts rate NEOG or MMSI?

Does the media favor NEOG or MMSI?

Is NEOG or MMSI more profitable?

Do insiders and institutionals have more ownership in NEOG or MMSI?

Which has more risk & volatility, NEOG or MMSI?

Which has higher earnings and valuation, NEOG or MMSI?

Summary

How does Neogen compare to ICU Medical?

Do analysts recommend ICUI or NEOG?

Does the media favor ICUI or NEOG?

Is ICUI or NEOG more profitable?

Which has more risk & volatility, ICUI or NEOG?

Do insiders & institutionals believe in ICUI or NEOG?

Which has higher valuation & earnings, ICUI or NEOG?

Summary

How does Neogen compare to Haemonetics?

Which has preferable earnings & valuation, HAE or NEOG?

Which has more volatility and risk, HAE or NEOG?

Do insiders and institutionals believe in HAE or NEOG?

Do analysts rate HAE or NEOG?

Does the media prefer HAE or NEOG?

Is HAE or NEOG more profitable?

Summary

How does Neogen compare to DENTSPLY SIRONA?

Does the media refer more to NEOG or XRAY?

Which has better earnings and valuation, NEOG or XRAY?

Is NEOG or XRAY more profitable?

Do analysts rate NEOG or XRAY?

Which has more risk & volatility, NEOG or XRAY?

Do institutionals & insiders have more ownership in NEOG or XRAY?

Summary

How does Neogen compare to STAAR Surgical?

Which has more risk and volatility, STAA or NEOG?

Do analysts rate STAA or NEOG?

Do insiders and institutionals hold more shares of STAA or NEOG?

Does the media favor STAA or NEOG?

Which has better valuation & earnings, STAA or NEOG?

Is STAA or NEOG more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEOG vs. The Competition

Neogen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools